Successful Control of Refractory Hidradenitis Suppurativa with Spesolimab: A Case Report

Authors

  • Yangfan Lai Department of Dermatology, Huashan Hospital, Fudan University, Shanghai, PR China
  • Yanzhuo Hu Department of Dermatology, Huashan Hospital, Fudan University, Shanghai, PR China
  • Xiaoyao Fan Department of Dermatology, Huashan Hospital, Fudan University, Shanghai, PR China
  • Baishuang Yue Department of Dermatology, Huashan Hospital, Fudan University, Shanghai, PR China
  • Ying Ma Department of Dermatology, Huashan Hospital, Fudan University, Shanghai, PR China

DOI:

https://doi.org/10.2340/actadv.v105.43329

Keywords:

Hidradenitis Suppurativa, Case Report, Spesolimab, IL-36 receptor, NETs

Downloads

Download data is not yet available.

References

Krueger JG, Frew J, Jemec GBE, Kimball AB, Kirby B, Bechara FG, et al. Hidradenitis suppurativa: new insights into disease mechanisms and an evolving treatment landscape. Br J Dermatol 2024; 190: 149–162. https://doi.org/10.1093/bjd/ljad345 DOI: https://doi.org/10.1093/bjd/ljad345

Zouboulis CC, Bechara FG, Fritz K, Goebeler M, Hetzer FH, Just E, et al. S2k guideline for the treatment of hidradenitis suppurativa / acne inversa – Short version. J Dtsch Dermatol Ges 2024; 22: 868–889. DOI: https://doi.org/10.1111/ddg.15412

McCarthy S. Hidradenitis suppurativa. Annu Rev Med 2025; 76: 69–80. DOI: https://doi.org/10.1146/annurev-med-051223-031234

Zouboulis CC, Frew JW, Giamarellos-Bourboulis EJ, Jemec GBE, Del Marmol V, Marzano AV, et al. Target molecules for future hidradenitis suppurativa treatment. Exp Dermatol 2021; 30: 8–17. DOI: https://doi.org/10.1111/exd.14338

Ogawa Y, Muto Y, Kinoshita M, Shimada S, Kawamura T. Neutrophil extracellular traps in skin diseases. Biomedicines 2021; 9: 1888. DOI: https://doi.org/10.3390/biomedicines9121888

Fukaura R, Akiyama M. Targeting IL-36 in inflammatory skin diseases. BioDrugs 2023; 37: 279–293. DOI: https://doi.org/10.1007/s40259-023-00587-5

Blair HA. Spesolimab: first approval. Drugs 2022; 82: 1681–1686. DOI: https://doi.org/10.1007/s40265-022-01801-4

Alavi A, Prens EP, Kimball AB, Frew JW, Krueger JG, Mukhopadhyay S, et al. Proof-of-concept study exploring the effect of spesolimab in patients with moderate-to-severe hidradenitis suppurativa: a randomized double-blind placebo-controlled clinical trial. Br J Dermatol 2024; 191: 508–518. DOI: https://doi.org/10.1093/bjd/ljae144

Downloads

Published

2025-06-23

How to Cite

Lai, Y., Hu, Y., Fan, X., Yue, B., & Ma, Y. (2025). Successful Control of Refractory Hidradenitis Suppurativa with Spesolimab: A Case Report. Acta Dermato-Venereologica, 105, adv43329. https://doi.org/10.2340/actadv.v105.43329

Issue

Vol. 105 (2025)

Section

Short Communication

Categories

License

Copyright (c) 2025 Yangfan Lai, Yanzhuo Hu, Xiaoyao Fan, Baishuang Yue, Ying Ma

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.

Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.

Crossref
Scopus
Google Scholar
Europe PMC